Liver growth factor promotes the survival of grafted neural stem cells in a rat model of Parkinson's disease.

Abstract

Neural stem cells (NSCs) with self-renewal and multilineage potential are considered good candidates for cell replacement of damaged nerve tissue. Several studies have focused on the ability of the neurotrophic factors coadministration to improve the efficiency of grafted NSCs. Liver growth factor (LGF) is an hepatic mitogen that promotes regeneration of damaged tissues, including brain tissue. It has neurogenic activity and has partially restored the nigrostriatal dopaminergic system in an experimental model of Parkinson's disease. Present results demonstrate that in the dopamine- depleted striatum of 6-hydroxydopamine-lesioned rats, grafted NSCs retained their ability to differentiate into neurons, astrocytes, and oligodendrocytes. NSCs also differentiated into microglia/macrophages and endothelial cells. Thus, 23 ± 5.6% of them were inmunoreactive for isolectin IB4, and a small population integrated into blood vessels, showing an endothelial-like morphology. Intrastriatal infusion of LGF promoted the viability of the implants, and favored their differentiation to an endothelial-like phenotype. Moreover, LGF infusion raised the expression of the anti-apoptotic protein Bcl-2 by 3.9 ± 0.9 fold without affecting the levels of the pro-apoptotic protein Bax. Since LGF-treated rats also showed a significant reduction in apomorphine-induced rotational behavior, our results suggest that administration of this factor might be a convenient treatment for Parkinson's disease cell replacement therapies based on NSCs transplantation.

• Authors: Diana Reimers, Cristina Osuna, Rafael Gonzalo-Gobernado, Antonio S Herranz, Juan Jose Diaz-Gil, Adriano Jimenez-Escrig, Maria Jose Asensio, Cristina Miranda, Macarena Rodriguez-Serrano, Eulalia Bazan
• Journal: Current stem cell research & therapy (Curr Stem Cell Res Ther) Vol. 7 Issue 1 Pg. 15-25 (Jan 2012) ISSN: 2212-3946 [Electronic] United Arab Emirates
• PMID: 21190529 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Proto-Oncogene Proteins c-bcl-2
• Serum Albumin
• albumin-bilirubin complex
• Oxidopamine
• Bilirubin
• Serum Albumin, Human

Topics

• Animals
• Bilirubin (administration & dosage)
• Cell Differentiation (drug effects)
• Cell Survival (drug effects)
• Corpus Striatum (drug effects, pathology)
• Disease Models, Animal
• Dopaminergic Neurons (drug effects, metabolism, pathology)
• Endothelial Cells (pathology)
• Female
• Gene Expression Regulation (drug effects)
• Humans
• Oxidopamine (administration & dosage)
• Parkinson Disease (pathology, physiopathology, therapy)
• Proto-Oncogene Proteins c-bcl-2 (genetics, metabolism)
• Rats
• Rats, Sprague-Dawley
• Recovery of Function
• Serum Albumin (administration & dosage)
• Serum Albumin, Human
• Stem Cell Transplantation